Abstract
We describe here the development of a chemifluorescent competitive enzyme-linked immunosorbent assay (ELISA) that quantifies marinobufagenin (MBG) levels in biological fluids. Based on a polyclonal antibody raised against a novel MBG-bovine serum albumin conjugate, this assay achieved an MBG detection limit of less than 9pg/mL. MBG levels in various rat urine and serum samples were effectively determined using this methodology. Interassay variability averaged 9.8%, while intra-assay variability averaged 1.9 and 2.5% in representative serum and urine samples, respectively. Recovery of exogenously added MBG averaged 106%, and parallelism data further established the accuracy of the assay. Employment of this assay to detect MBG abnormalities represents a powerful tool for the possible diagnosis, prevention and management of human hypertensive states, particularly preeclampsia.
Original language | English (US) |
---|---|
Pages (from-to) | 31-46 |
Number of pages | 16 |
Journal | Journal of Immunoassay and Immunochemistry |
Volume | 32 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2011 |
Keywords
- bufodienolides
- cardiac glycosides
- diagnostic
- hypertension
- immunoassay
- marinobufagenin
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Clinical Biochemistry
- Medical Laboratory Technology